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Abstract
One of the factors involved in accelerated atherosclerosis in hemodialysis patients is
dyslipidemia. In this study we considered factors involved in intensification of dyslipidemia
in hemodialysis patients.This study was done on 36 maintenance hemodialysis patients.
Serum lipoprotein (a), triglyceride, cholesterol, HDL-C, LDL-C and serum Intact
Parathormone (iPTH), Ca, P, Magnesium were measured.In statistical analysis there was
no correlation between serum lipids levels and iPTH, serum calcium and CaxP product
(p>0.05). There was a positive correlation between serum magnesium and lipoprotein(a)
and also between serum magnesium levels with serum triglyceride level (P<0.05).
Magnesium doesn’t directly increase lipoprotein synthesis. It may be involved in the
regulation of enzymes responsible for lipoprotein synthesis. Correlation of serum
magnesium with serum triglyceride can be due to changes in hepatic triglyceride
metabolism. Lipoprotein(a) is a non traditional factor of premature atherosclerosis, its
association with increase in serum magnesium needs to be investigated in hemodialysis
patients.
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Introduction
Hemodialysis patients have a number of biochemical
abnormalities including hyperlipidemia. The
cardiovascular illness is an important cause of death in
hemodialysis patients1. Hyperlipidemia has been
incriminated as a risk factor of atherosclerotic vascular
disease in dialyzed patients2. Hemodialysis is associated
with hypertriglyceridemia. The other dyslipidemias
consist of (a) high serum lipoprotein levels (b) low serum
high density lipoprotein. Plasma low density lipoprotein
(LDL) cholestrol is usually not elevated1-3. The cause of
hypertriglyceridemia is an increased production of Apo
B protein and a marked decrease in the metabolism of
VLDL, primarily as a result of decreased endothelial cell
delipidation of VLDL2. Magnesium (Mg) retention can
occur in patients on maintenance hemodialysis.
Magnesium deficiency has a role in the disturbances of
lipid metabolism in the non-uremic population.
Furthermore other reports show that there is correlation
between dyslipidemia and high magnesium level in
hemodialysis patients4. This study evaluates the
association of serum magnesium and the disturbances
in lipid profile in patients on maintenance hemodialysis
treatment due to end-stage renal failure.
Materials & methods
This study included thirty-six patients under regular
hemodialysis due to end-stage renal failure. For 3 years
all the patients were hemodialyzed with polysulfone
membrane hollow fibers. Patients underwent thrice or
twice weekly hemodialysis. The duration of each
hemodialysis session was four hours. The magnesium
concentration in the dialysate fluid was 1mEq / lit. Factors
used for exclusion were: use of antilipid drug and active
or chronic infection. Plasma cholesterol (Chol)
triglyceride (Tg), high- density lipoprotein-cholestrol
(HDL-C), lipoprotein (a) [Lp(a)] and Intact Parathormone
(iPTH) serum magnesium (Mg), calcium (Ca),
phosphorus(P) were measured. Low-density lipoprotein-
cholestrol (LDL-C) was calculated by Friedewald’s
formula5. Lipoprotein (a) was measured by enzyme
immunoassay (ELISA) with Immuno-biological
laboratories (IBL) kit (Germany). Other lipids were
measured by standard kits. iPTH was measured by RIA
4 7
Copyright © 2004 by The Indian Society of Nephrology
Indian J Nephrol 2004;14: 46-49
with DSL-8000 kit (USA). Magnesium was measured
by colorimetric method. For correlations Spearman rho
test was used and P value less than 0. 05 was considered
significant.
Results
Total patients were thirty-six (F=16 M=20) with mean
age of 47. 5±16. 6years. The length of the time patients
had been on hemodialysis was 25±24. 4 months. Table
1 show values of biochemical and hormonal levels. In
this study, there was a significant positive correlation
between serum magnesium and lipoprotein (a) (r=0.65,
P<0. 05) (Figure 1). Significant positive correlation
between serum magnesium and triglyceride level
(r=0.32, P<0. 05) was observed too (Figure 2). There
was no significant correlation between serum
magnesium with cholesterol, HDL-C, and LDL-C (p>0.
05) (Figures 3 and 4). There was no correlation between
serum calcium, iPTH and Ca x P product with serum
lipids (P>0. 05).
Discussion
In this study there was a positive correlation between
serum Mg levels and serum LP(a). Significant positive
correlation of serum Mg levels with Tg was seen too,
which means high serum Mg in hemodialysis patients
might be associated with some types of dyslipidemia
seen in hemodialysis patients. Uremic patients
undergoing hemodialysis had dyslipidemia consisting of
high serum Tg and LP(a) levels without increase in serum
cholesterol, while high-density lipoprotein-cholesterol
levels have generally been found to be decreased1,2,6. It
is well documented that lipid profile, specially high serum
LP(a) and low HDL-C is highly atherogenic and is one
of the factors that accelerates atherosclerosis seen in
these patients on maintenance hemodialysis1-4,6. It has
Table 1 - The results of biochemical investigations
Figure 1: Correlation of magnesium  with serum  Lp(a)
values (r=0.65 ,p<0.05).
Figure 2: Correlation of magnesium  with serum  triglyceride
values (r=0.32 ,p<0.05).
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Figure 4: Correlation of magnesium  with serum     LDL
values(r=0.047,P>0.05)
been suggested that Mg deficiency is related to alteration
in lipid metabolism4. Some animal studies have shown
that Mg- deficient diet is associated with high serum Tg
or cholesterol levels. But in Mg-deficient non-uremic rats,
no changes in serum cholesterol were found8,9. It has
been reported that in uremic rats, magnesium deficiency
increased Tg levels and decreased HDL-chol levels10.
In contrast, magnesium hydroxide (548 mg/dl in males
and 411 mg/dl for females) used for 4 weeks showed a
significant improvement in blood pressure. Also the
HDL:LDL ratio and total cholesterol improved with the
magnesium treatment11. A study in twenty-five
hemodialysis patients reported a positive significant
correlation between serum magnesium levels and serum
total cholesterol, and serum triglycerides4. In contrast
to this study we found no positive correlation between
seurm cholesterol with serum magnesium levels, though
there was a positive correlation between serum
magnesium and serum triglyceride levels. Lipoprotein(a)
is an independent risk factor for atherosclerotic
cardiovascular disease (CVD) in general population and
dialysis patients3. In this study we found a significant
correlation between serum magnesium and LP(a) levels.
Serum LP (a) elevation in hemodialysis patients can be
due to uremia that could influence LP(a) metabolism.
The kidneys may also play a role in LP(a) catabolism
and the end-stage renal disease might result in elevated
LP(a) levels2,6,7. Based on recent observations, showing
significant correlations between serum lipoprotein (a),
IL-6 and TNF- Levels, it is hypothesized that an activated
acute phase reaction may be the underlying cause for
high levels of lipoprotein (a) found in patients receiving
chronic hemodialysis4,11. Mg does not seem to increase
lipoprotein synthesis. It may be involved in the regulation
of enzymes responsible for lipoprotein synthesis4. While
there was a trend towards an increase in triglyceride
levels with increasing magnesium levels, it could be due
to changes in hepatic triglyceride metabolism induced
by magnesium4. Further clinical studies into the effect
of serum magnesium on lipoprotien metabolism are
required in hemodialysis patients.
Figure 3: Correlation of magnesium  with serum
cholesterol values (r=0.097,P>0.05)
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